ALCHEMIA SHARES PLUNGE

Written on the 28 October 2014

ALCHEMIA SHARES PLUNGE

SHARES in Alchemia (ASX:ACL) have dived 83 per cent after the company announced its metatastic colorectal cancer trial had failed.

The treatment tested Alchemia’s HyAct technology formulated with chemotherapeutic drug irinotecan over using irinotecan alone.

HA-irinotecan did not improve progression free survival in patients.

Alchemia CEO Thomas Liquard says the company will conduct an in-depth review of the trial.

“We are extremely disappointed in the outcome of this trial and extend our appreciation to trial investigators, the clinical sites and the hundreds of patients who participated in this study,” Liquard says.

“We expect to report back to the scientific community and the market with further details on our data reviews and corporate strategy early in 2015.”

The drug development company’s financial position includes $8.9 million in cash and a $6.5 million research and tax development tax incentive to be received next month.

ACL is trading at $0.098 per share.


Latest News

CORPORATE TRAVEL MANAGEMENT POSTS STRONG FIRST HALF RESULT

CORPORATE Travel Management (ASX:CTD) battled headwinds including a falling Australian Dollar and an airline price wa...

SLATER AND GORDON FILES CLASS ACTION AGAINST BELLAMY'S

SLATER AND GORDON (ASX:SGH), with funding from IMF Bentham (ASX:IMF), has filed its class action against Bellamy...

BILLABONG'S SALES DEPARTMENT STILL STRUGGLING

SURFWEAR retailer Billabong International (ASX: BBG) hasn't posted any surprises to the ASX.

The Burleigh Head...

EVERYTHING YOU NEED TO KNOW ABOUT THE NATIONAL BROADBAND NETWORK

THE National Broadband Network (NBN) is more than an internet connection, it is an opportunity to transform your b...

Related News

EVERYTHING YOU NEED TO KNOW ABOUT THE NATIONAL BROADBAND NETWORK

THE National Broadband Network (NBN) is more than an internet connection, it is an opportunity to transform your b...

WHY EMPLOYEE-OWNED COMPANIES ARE BEATING ASX200 SHARE PRICES

EMPLOYEE-owned companies command a higher share price than their publicly listed peers, reaping a 17 per cent prem...

RISE OF THE MACHINES HAS WORKERS SWEATING

UP TO 3.8 million Australian workers are fearful their job may soon be terminated by a robot, a new survey has shown....

LESS TALK, MORE SMALL BUSINESS ACTION IN 2017

THE future growth and prosperity of Australian SMEs could be undermined if governments lose sight of the sector...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter